Skip to main content
. Author manuscript; available in PMC: 2022 Jun 4.
Published in final edited form as: J Drug Target. 2021 Feb 1;29(7):754–760. doi: 10.1080/1061186X.2021.1878364

Figure 2.

Figure 2.

C3-liposomes encapsulating TLR agonists increase expression of inflammatory cytokines in myeloid cells. Murine bone marrow derived cells were treated with PBS, control-liposomes, C3-liposomes, control-liposomes encapsulating TLR agonists (+Adj.), or C3-liposomes encapsulating TLR agonists (+Adj.) for 24 h. RT-PCR was used to analyse the relative expression of IRF7, IP-10, IL-1β, IL-6, IL-12, and TNF-α mRNAs in response to treatments. Data are expressed as mean ± standard error (n = 3) and normalised to PBS controls. *p Value < .05.